BioSyntech Inc., of Laval, Quebec, was issued U.S. Patent No. 6,344,488 covering its BST-Gel technology. Several products are being developed based on the BST-Gel platform for delivery of therapeutic agents and soft- and hard-tissue repair.
Sunesis Pharmaceuticals Inc., of South San Francisco, was issued U.S. Patent No. 6,344,334 covering a component of its Target-Directed Lead Discovery program. The patent is exclusively licensed from the University of California.
Vaxin Inc., of Birmingham, Ala., received U.S. Patent No. 6,348,450 B1, titled “Non-Invasive Genetic Immunization, Expression Products Therefrom and Uses Thereof.” Vaxin has an exclusive license to this technology from the University of Alabama at Birmingham Research Foundation.